DiaceuticsFRA:7DC +1.23%90 EV-to-FCF is -22.31 as of Jul. 02, 2026. GuruFocus rates FRA:7DC with a GF Score™ of 90/100 and a GF Value™ of €2.13 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 406 Healthcare Providers & Services companies, Diaceutics ranks worse than 246305.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Diaceutics's Enterprise Value is €136.05 Mil.
Diaceutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.10 Mil. Therefore, Diaceutics's EV-to-FCF for today is -22.31.
The historical rank and industry rank for Diaceutics's EV-to-FCF or its related term are showing as below:
FRA:7DC'
s EV-to-FCF Range Over the Past 10 Years
Min: -32.71 Med: -19.74 Max: 359.97
Current: -22.28
During the past 10 years, the highest EV-to-FCF of Diaceutics was 359.97. The lowest was -32.71. And the median was -19.74.
FRA:7DC's EV-to-FCF is ranked worse than 100% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.57
vs FRA:7DC: -22.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diaceutics's share price for today is €1.64.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diaceutics EV-to-FCF Related Terms
Diaceutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Diaceutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diaceutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Diaceutics's EV-to-FCF falls into.
Diaceutics's current Enterprise Value is €136.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (FRA:7DC) has a EV-to-FCF of -22.31 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #999999 out of 406 companies in the Healthcare Providers & Services industry.
Is Diaceutics' EV-to-FCF too high?
Diaceutics' current EV-to-FCF is -22.31. Based on the distribution chart, Diaceutics ranks #999999 out of 406 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #999999 out of 406 companies for EV-to-FCF. This places Diaceutics in the lower half of its industry. The industry median EV-to-FCF is 17.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.57, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current EV-to-FCF is -22.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.13, compared to a current price of €1.64 — trading 23% below its estimated fair value. The current EV-to-FCF is -22.31. Diaceutics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current EV-to-FCF is -22.31 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (FRA:7DC) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of €1.64 is trading 23% below its estimated GF Value™ of €2.13.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for FRA:7DC:
EV-to-FCF: -22.31
GF Value™: €2.13 vs. price of €1.64 (23% below fair value)
No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
90GF Score
Get the complete analysis for FRA:7DC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7DC has been successfully added to your 
